Literature DB >> 8129866

Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases.

D M Parent-Massin1, L Sensébé, M C Léglise, G Guern, C Berthou, C Riché, J F Abgrall.   

Abstract

Bone marrow colony forming unit-granulocyte macrophage (CFU-GM) cultures of 14 patients after neutrophil recovery from drug-induced agranulocytosis (median 12 weeks) were performed in the presence of 20 different drugs and/or acute-phase serum (APS) obtained during agranulocytosis. In 10 cases, drugs involved in agranulocytosis in vivo caused a significant inhibition of CFU-GM growth in vitro in comparison with normal cultures without drug. Three types of direct toxicity are suggested: (i) a decrease in the rate of mitosis; (ii) a destruction of cells (cytotoxic effect); or (iii) a blockage in progenitor mitosis (cytostatic effect). A humoral mechanism was suggested in 1 case because of enhanced inhibition with APS. In 4 cases no effect of the suspected drug could be detected by in vitro studies, but all hypotheses have not been tested in these cases, particularly the possible role of APS and other substances.

Entities:  

Mesh:

Year:  1993        PMID: 8129866     DOI: 10.2165/00002018-199309060-00009

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  17 in total

1.  Amidopyrine agranulocytosis:drug inhibition of granulocyte colonies in the presence of patient's serum.

Authors:  A J Barrett; E Weller; N Rozengurt; P Longhurst; J G Humble
Journal:  Br Med J       Date:  1976-10-09

2.  Prospective in vitro testing for drug-induced neutropenia in a patient requiring anti-malarial prophylaxis: confirmation of findings on exposure of patient to drug.

Authors:  C A Humphrey; A French; T C Morris
Journal:  Clin Lab Haematol       Date:  1990

3.  Mechanism of aprindine induced agranulocytosis: direct toxicity on CFU-C and CFU-GEMM.

Authors:  M A Boogaerts; M Peters; C Peersman; H Kesteloot; R L Verwilghen
Journal:  Scand J Haematol       Date:  1984-02

4.  Drug-induced agranulocytosis: evidence for the commitment of bone marrow haematopoiesis.

Authors:  W Heit; H Heimpel; A Fischer; N Frickhofen
Journal:  Scand J Haematol       Date:  1985-11

5.  Drug-induced agranulocytosis: in vitro evidence for immune suppression of granulopoiesis and a cross-reacting lymphocyte antibody.

Authors:  R Taetle; T A Lane; J Mendelsohn
Journal:  Blood       Date:  1979-08       Impact factor: 22.113

6.  Amodiaquine-induced agranulocytosis: toxic effect of amodiaquine in bone marrow cultures in vitro.

Authors:  D E Lind; J A Levi; P C Vincent
Journal:  Br Med J       Date:  1973-02-24

7.  In vitro medullary granulocytic progenitor (CFUc) cultures from 6 cases of granulocytopenias.

Authors:  C Parmentier; G Tchernia; E Subtil; L Diakhate; N Morardet
Journal:  Scand J Haematol       Date:  1978-07

8.  Quinidine-induced neutropenia: report of a case with drug-dependent inhibition of granulocyte colony generation.

Authors:  J L Ascensao; P J Flynn; A Slungaard; W Wachsman; E D Zanjani; H S Jacob
Journal:  Acta Haematol       Date:  1984       Impact factor: 2.195

9.  Procainamide-induced agranulocytosis with reversible myeloid sensitivity.

Authors:  J C Nelson; J D Lutton; A E Fass
Journal:  Am J Hematol       Date:  1984       Impact factor: 10.047

10.  The use of in vitro technics to study drug-induced pancytopenia.

Authors:  J G Kelton; A T Huang; N Mold; G Logue; W F Rosse
Journal:  N Engl J Med       Date:  1979-09-20       Impact factor: 91.245

View more
  2 in total

1.  A cellular model for drug interactions on hematopoiesis: the use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis.

Authors:  M C Léglise; P Darodes de Tailly; J L Vignot; M A Le Bot; A M Le Roux; C Riché
Journal:  Cell Biol Toxicol       Date:  1996-02       Impact factor: 6.691

Review 2.  Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.

Authors:  R E Parchment
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.